CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Evolution of cancer therapeutics has resulted in the development of agents with varying mechanisms of selective target inhibition. One such therapeutic approach is utilizing antibody-drug conjugates (ADCs), the combination of a cytotoxic agent linked with a monoclonal antibody, to achieve localization of the target and internalization of the cytotoxic agent in order to maximize efficacy with fewer toxicities. This review focuses on CD30 as a therapeutic target and the development and clinical activity of the ADC brentuximab vedotin in Hodgkin lymphoma (HL) and other B cell lymphomas.
The Ohio State University James Comprehensive Cancer Center, 420 West 10th Avenue, A348 Starling Loving Hall, Columbus, OH, 43210, USA.
Geetika
G
Bhatt
The Ohio State University James Comprehensive Cancer Center, 420 West 10th Avenue, A348 Starling Loving Hall, Columbus, OH, 43210, USA.
Kami
K
Maddocks
The Ohio State University James Comprehensive Cancer Center, 420 West 10th Avenue, A348 Starling Loving Hall, Columbus, OH, 43210, USA. beth.christian@osumc.edu.
Beth
B
Christian
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry / Q000627:therapeutic use; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D016879:Salvage Therapy; D033581:Stem Cell Transplantation
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin
Antibody-drug conjugate; Brentuximab vedotin; Hodgkin lymphoma; Non-Hodgkin lymphoma